GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Tax Provision

BioVaxys Technology (XCNQ:BIOV) Tax Provision : C$0.00 Mil (TTM As of Jan. 2025)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Tax Provision?

BioVaxys Technology's tax provision for the three months ended in Jan. 2025 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jan. 2025 was C$0.00 Mil.

BioVaxys Technology Tax Provision Historical Data

The historical data trend for BioVaxys Technology's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Tax Provision Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Tax Provision
Get a 7-Day Free Trial - - - - -

BioVaxys Technology Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioVaxys Technology Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Tax Provision
Comparable Companies
TSXV:HEM TSX:CSCI TSXV:KNE XCNQ:PREV TSX:RVX TSX:APS XCNQ:BLAB XCNQ:BETR TSXV:SBM XCNQ:GLOW VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
BVAXF:USA 5LB:Germany
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
Website
https://www.biovaxys.com
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Executives
James Passin Director, Senior Officer
Kenneth Kovan Senior Officer

BioVaxys Technology Headlines

No Headlines